• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Replimune Group Inc.

    7/25/25 4:18:29 PM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $REPL alert in real time by email
    DEFA14A 1 tm2521674d3_defa14a.htm DEFA14A

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of
    the Securities Exchange Act of 1934
    (Amendment      
    )

     

    Filed by the Registrant x

     

    Filed by a Party other than the Registrant ¨

     

    Check the appropriate box:

     

    ¨ Preliminary Proxy Statement

     

    ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ¨ Definitive Proxy Statement

     

    x Definitive Additional Materials

     

    ¨ Soliciting Material under §240.14a-12

     

    REPLIMUNE GROUP, INC.

    (Name of Registrant as Specified In Its Charter)

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

     

    x No fee required.

     

    ¨ Fee paid previously with preliminary materials.

     

    ¨ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11

     

     

     

     

     

    GRAPHIC

    Step 1: Go to www.envisionreports.com/REPL. Step 2: Click on Cast Your Vote or Request Materials. Step 3: Follow the instructions on the screen to log in. www.envisionreports.com/REPL Online Go to www.envisionreports.com/REPL or scan the QR code — login details are located in the shaded bar below. 2025 Annual Meeting of Replimune Group, Inc. Notice 046B8B Important Notice Regarding the Availability of Proxy Materials for the 2025 Annual Meeting of Stockholders of Replimune Group, Inc. to be Held on September 3, 2025 Under Securities and Exchange Commission rules, you are receiving this notice that the proxy materials for the annual stockholders’ meeting are available on the Internet. Follow the instructions below to view the materials and vote online or request a copy. The items to be voted on and location of the annual meeting are on the reverse side. Your vote is important! This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. Replimune’s 2025 Proxy Statement and Annual Report on Form 10-K for the fiscal year ended March 31, 2025 are available at: Obtaining a Copy of the Proxy Materials – If you want to receive a copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. Please make your request as instructed on the reverse side on or before August 22, 2025 to facilitate timely delivery. 2NOT Easy Online Access — View your proxy materials and vote. When you go online, you can also help the environment by consenting to receive electronic delivery of future materials. The Sample Company Step 4: Make your selections as instructed on each screen for your delivery preferences. Step 5: Vote your shares.

    GRAPHIC

    Here’s how to order a copy of the proxy materials and select delivery preferences: Current and future delivery requests can be submitted using the options below. If you request an email copy, you will receive an email with a link to the current meeting materials. PLEASE NOTE: You must use the number in the shaded bar on the reverse side when requesting a copy of the proxy materials. — Internet – Go to www.envisionreports.com/REPL. Click Cast Your Vote or Request Materials. — Phone – Call us free of charge at 1-866-641-4276. — Email – Send an email to [email protected] with “Proxy Materials Replimune Group, Inc.” in the subject line. Include your full name and address, plus the number located in the shaded bar on the reverse side, and state that you want a paper copy of the meeting materials. To facilitate timely delivery, all requests for a paper copy of proxy materials must be received by August 22, 2025. The 2025 Annual Meeting of Stockholders of Replimune Group, Inc. will be held on Wednesday, September 3, 2025 at 11:30 A.M. Eastern time, virtually via the internet at meetnow.global/MF6VJVT. To access the virtual meeting, you must have the information that is printed in the shaded bar located on the reverse side of this form. Proposals to be voted on at the meeting are listed below along with the Board of Directors’ recommendations. The Board of Directors recommend a vote FOR all the nominees listed and FOR Proposals 1-4: 1. Election of Directors: 01 - Kapil Dhingra 02 - Christy Oliger 03 - Joseph Slattery 04 - Michael Goller 05 - Philip Astley-Sparke 2. To ratify the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for Replimune Group, Inc. for the fiscal year ending March 31, 2026. 3. To approve, on a non-binding advisory basis, the compensation of Replimune Group, Inc.’s named executive officers for the fiscal year ended March 31, 2025. 4. To approve an amendment to Replimune Group, Inc.’s 2018 Omnibus Incentive Compensation Plan (the “Plan Amendment”). PLEASE NOTE – YOU CANNOT VOTE BY RETURNING THIS NOTICE. To vote your shares you must go online or request a paper copy of the proxy materials to receive a proxy card. If you wish to attend and vote at the meeting, please bring this notice with you. 2025 Annual Meeting of Stockholders of Replimune Group, Inc.

    Get the next $REPL alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $REPL

    DatePrice TargetRatingAnalyst
    7/23/2025$2.00Outperform → Underperform
    BMO Capital Markets
    7/23/2025Buy → Neutral
    H.C. Wainwright
    7/23/2025$3.00Overweight → Equal Weight
    Barclays
    7/22/2025$3.00Outperform → Market Perform
    Leerink Partners
    7/22/2025$9.00Overweight → Neutral
    Analyst
    7/22/2025$4.00Outperform → Neutral
    Wedbush
    7/22/2025$3.00Overweight → Neutral
    Piper Sandler
    6/20/2025Overweight
    Cantor Fitzgerald
    More analyst ratings

    $REPL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Replimune Receives Complete Response Letter from FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma

      WOBURN, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma. The CRL indicates that the FDA is unable to approve the application in its present form. The FDA has indicated that the IGNYTE trial is not considered to be an adequate and well-controlled clinical investigation that provides substantial eviden

      7/22/25 7:00:00 AM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      WOBURN, Mass., July 11, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees. The Company granted equity awards to 16 employees as a material inducement to commencing their employment with the Company under the Company's 2025 Inducement Grant Incentive Compensation Plan (the "Inducement Plan"). The inducement awards consist of non-qualified stock options to purchase an aggregate of 32,135 shares of the Company's common stock and restricted stock units representing an aggregate of 64,320 s

      7/11/25 4:01:00 PM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      WOBURN, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees. The Company granted equity awards to 10 employees as a material inducement to commencing their employment with the Company under the Company's 2025 Inducement Grant Incentive Compensation Plan (the "Inducement Plan"). The inducement awards consist of non-qualified stock options to purchase an aggregate of 36,485 shares of the Company's common stock and restricted stock units representing an aggregate of 41,080 s

      6/6/25 4:01:00 PM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $REPL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Astley-Sparke Philip sold $260,169 worth of shares (32,279 units at $8.06), decreasing direct ownership by 2% to 1,405,071 units (SEC Form 4)

      4 - Replimune Group, Inc. (0001737953) (Issuer)

      5/22/25 9:47:07 PM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Medical Officer Xynos Konstantinos sold $64,093 worth of shares (7,952 units at $8.06), decreasing direct ownership by 5% to 146,933 units (SEC Form 4)

      4 - Replimune Group, Inc. (0001737953) (Issuer)

      5/22/25 9:46:09 PM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Accounting Officer Schwendenman Andrew sold $26,460 worth of shares (3,287 units at $8.05), decreasing direct ownership by 5% to 68,284 units (SEC Form 4)

      4 - Replimune Group, Inc. (0001737953) (Issuer)

      5/22/25 9:45:30 PM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $REPL
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Replimune Group Inc.

      DEFA14A - Replimune Group, Inc. (0001737953) (Filer)

      7/25/25 4:18:29 PM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Replimune Group Inc.

      DEF 14A - Replimune Group, Inc. (0001737953) (Filer)

      7/25/25 4:16:04 PM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Replimune Group Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Replimune Group, Inc. (0001737953) (Filer)

      7/22/25 8:18:47 AM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $REPL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Replimune downgraded by BMO Capital Markets with a new price target

      BMO Capital Markets downgraded Replimune from Outperform to Underperform and set a new price target of $2.00

      7/23/25 7:43:21 AM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Replimune downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Replimune from Buy to Neutral

      7/23/25 7:42:18 AM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Replimune downgraded by Barclays with a new price target

      Barclays downgraded Replimune from Overweight to Equal Weight and set a new price target of $3.00

      7/23/25 7:42:18 AM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $REPL
    Financials

    Live finance-specific insights

    See more
    • Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day

      WOBURN, Mass., May 16, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that it will host a conference call on Thursday, May 22, 2025 at 8:00 a.m. ET to discuss its financial results for the fiscal fourth quarter and year end March 31, 2025. Additionally, the Company will host an Investor Day on Tuesday, June 24, 2025. Fiscal Fourth Quarter Earnings Replimune will release its fiscal year end earnings and host a conference call at 8:00 a.m. ET on May 22, 2025. Listeners can register for the webcast via this link. Analysts wishing to participate in the

      5/16/25 8:00:00 AM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma

      Primary endpoint data shows 12-month overall response rate (ORR) of 33.6% Biologics license application (BLA) submission intended for 2H 2024; first patient expected to be enrolled in IGNYTE-3 confirmatory trial in Q3 2024 Company to host conference call and webcast today at 8:00 a.m. ET WOBURN, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced the topline results from the primary analysis of the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma. The results by independent central review show one-third of pat

      6/6/24 7:00:00 AM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers

      RP1 in combination with cemiplimab demonstrated clinically meaningful improvements in complete response rate and duration of response compared to cemiplimab in the CERPASS clinical trial, but did not meet either of the two primary endpoints Positive data update for full 140 patients in the IGNYTE clinical trial cohort of RP1 in anti-PD1 failed melanoma reinforces durable benefit; biologics license application (BLA) submission planned for 2H 2024 RP1 monotherapy data from ARTACUS clinical trial and new data from first 30 patients with anti-PD1 failed non-melanoma skin cancers in IGNYTE trial adds to growing body of evidence supporting the potential of RP1 in difficult to treat skin cancer s

      12/5/23 7:00:00 AM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $REPL
    Leadership Updates

    Live Leadership Updates

    See more
    • Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors

      Milan, Italy, May 8, 2025 – Sibylla Biotech today announced the appointment of Dieter Weinand as Chairman of its Board of Directors. Mr. Weinand is an industry veteran, boasting over 35 years in the pharmaceutical sector, including leading business units and drug commercialization initiatives at global organizations. His background includes serving as President, CEO and Chairman of the Board of Bayer Pharmaceuticals AG. At Sibylla, Mr. Weinand's profound knowledge will guide the Board as the company advances its innovative Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT) technology and pipeline of folding interference small molecules to address a range of cha

      5/8/25 5:00:00 AM ET
      $COYA
      $REPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions

      Philip Astley-Sparke to transition from current role of CEO to Executive Chairman Planned leadership changes position the Company for commercialization Preparations on track to submit RP1 biologics license application (BLA) in 2H 2024 WOBURN, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced changes to its executive leadership team designed to support the Company's preparations for the commercial launch of RP1, pending regulatory submission and approval in anti-PD1 failed melanoma. Sushil Patel, Ph.D., will succeed Philip

      3/26/24 7:30:00 AM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tessellate BIO Emerges from Stealth

      The company aims to become a global leader in precision oncology by redefining Synthetic Lethality to treat large, currently unserved patient populationsLead program targets Alternative Lengthening of Telomeres (ALT) through the FANCM protein complexCompany backed by leading venture firms, BioGeneration Ventures (BGV) and ForbionWorld-class leadership team with proven experience as entrepreneurs and deep expertise in drug discovery and precision oncology AMSTERDAM and LONDON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Tessellate BIO, a preclinical stage biotechnology company with a focus on novel Synthetic Lethality approaches, has today emerged from stealth, with an initial €8m in s

      10/17/23 3:00:00 AM ET
      $NAMS
      $REPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $REPL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Replimune Group Inc.

      SC 13G/A - Replimune Group, Inc. (0001737953) (Subject)

      11/14/24 4:20:10 PM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Replimune Group Inc.

      SC 13G/A - Replimune Group, Inc. (0001737953) (Subject)

      11/14/24 1:22:38 PM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Replimune Group Inc.

      SC 13G/A - Replimune Group, Inc. (0001737953) (Subject)

      11/14/24 8:35:56 AM ET
      $REPL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care